clinical trial · NCT07671001
A Study of Depemokimab in Participants of 6 to 11 Years of Age
AsthmaDepemokimab
brief summary
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.
started
Jun 25, 2026
primary completion
Mar 1, 2027
completion
Nov 24, 2028
last updated
Aug 26, 2026
official title
A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol